DNA Damage Response Market

DNA Damage Response Market by Target Disease Indication, Therapeutic Area, Target Molecule, Type of Molecule, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    96

  • Pages
    265

  • View Count
    11592

DNA Damage Response Market Overview

The DNA damage response market is estimated to be worth $13 million in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 73% during the forecast period. According to the WHO, cancer is presently the second leading cause of death, worldwide. As per GLOBOCAN, the number of patients diagnosed with various types of cancer in the US, crossed the 19 million mark in 2020. By 2030, it is estimated that the aforementioned number is likely to grow to over 22 million. Over time, it has been established that the conventional approaches, such as chemotherapy, surgery and radiation therapy, to treating oncological indication(s) are inadequate, especially when it comes to late-stage cancers. In fact, several of the traditional interventions are designed to eliminate cancerous tissue by damaging the genetic material (DNA) contained in the malignantly transformed cells, in order to trigger programmed cell death. However, if the therapeutic-induced DNA damage is repaired, the cells survive. This is also the basis for why specific patient populations become resistant to certain forms of therapy. Over the years, scientific enquiry into the genetic causes of the malignant transformation have recognized defects and tumor microenvironment induced upregulation of specific cellular pathways, which are deemed to be responsible for the identification / repair of DNA damage and the resulting resistance to the traditional forms of treatment. These are now considered to be reliable disease biomarkers and thereby, viable biological targets for targeted drug development initiatives.   

The DNA damage response (DDR) comprises of orchestrated network of pathways that signal not only for repair of DNA lesions but also for activation of checkpoints, which are responsible for cell arrest at key points in the cell cycle. Importantly, high specificity and sensitivity to conventional therapies, coupled to minimal off target toxicity, have led to the use of DDR as a potential target for treatment of wider range of clinical conditions (both oncological and non-oncological). In this regard, several researchers across the globe have developed / developing DDR inhibitors to overcome DDR-mediated resistance to DNA-damaging anticancer therapy and exploit DDR dysfunction in oncological indication by targeting alternative pathways. 

Currently, there are four approved poly-ADP ribose polymerase (PARP) inhibitor drugs that are based on the inhibition of the DNA damage repair process in advanced stage oncological indications. Further, drug developers across the world, claim to be evaluating several other molecular targets, such as ATM, ATR, CHK1, and WEE1, within the DNA damage response pathway.  Although majority of the drug candidates for molecular targets (other than PARP) are in the preclinical / initial clinical stages, drug developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Gradually, a substantial body of evidence, validating the efficacy of drugging the aforementioned biological targets, is being generated through extensive research in DNA damage response market; this is reflected in the rapidly growing number of research publications and patents focused on this subject. Driven by encouraging clinical trial results, this niche, but upcoming market, is poised to witness healthy market growth during the forecast period, with pioneers in the field likely to benefit from the first-to-market advantage.

Context of DNA Damage Response Market List of DNA Damage Response Targeting Therapies in DNA Damage Response Market Market Landscape of Market Trends in DNA Damage Response Market

Key Companies in DNA Damage Response Market

Examples of key companies engaged in developing therapeutics in DNA damage response market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aprea Therapeutics, AstraZeneca, Chordia Therapeutics, Mission Therapeutics, Repare Therapeutics and Senhwa Biosciences. This market report includes an easily searchable excel database of all the companies developing DNA damage response targeting drugs, worldwide.

Recent Developments in DNA Damage Response Market:

Several recent developments have taken place in the field of DNA damage response market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, the FDA approved Investigational New Drug (IND) Application for CT7439, a Novel CDK12/13 inhibitor, to treat multiple types of advanced solid tumors. 
  • In July 2023, KSQ Therapeutics entered into a license agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small molecule inhibitor of USP1, a protein that regulates DNA damage response.

Scope of the Report

The “DNA Damage Response Market (beyond PARP inhibitors) Market by Target Disease Indication (Acute Myeloid Leukemias, COVID-19, Diabetic Macular Edemas, Mesotheliomas, Myelodysplastic Syndromes, Non-Squamous Non-Small Cell Lung Cancers, Prostate Cancers, Uterine Serous Carcinomas), Therapeutic Area (Hematological Malignancies, Solid Tumors, and Other Disorders), Target Molecule (APE1/Ref-1, Casein Kinase 2, CHK-1, C-Tak, DHODH, MAPKAPK2, p53, and WEE 1), Type of Molecule (Biologics and Small Molecule), Route of Administration (Oral Drugs and Intravenous Drugs), and by Key Geographical Regions (US, Canada, Denmark, France, Germany, Italy, Spain, UK, Australia,  Singapore, and South Korea): Industry Trends and Global Forecasts, 2021-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the DNA damage response market. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in DNA damage response market.

Clinical Trials Analysis in DNA Damage Response Market Publication Analysis in DNA Damage Response Market Multivariate Scenario Analysis in DNA Damage Response Market

Amongst other elements, the market research report includes:

  • A detailed review of the current market landscape of DNA damage response targeting therapeutics, including information on phase of development (clinical and preclinical), target disease indication(s), therapeutic area (hematological malignancies, immune-oncological disorders, neurological disorders, solid tumors, unspecified oncological disorders, and other disorders), target molecule, type of molecule (biological and small molecules), type of therapy (monotherapies, and combination therapies), dosage form (solid, and liquid), route of administration (intravenous, subcutaneous, and oral), and special drug designation awarded (if any). In addition, it highlights the companies engaged in the development of DNA damage response targeting therapeutics, along with information on their year of establishment, company size (in terms of employee count) and location of respective headquarters.
  • An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in DNA damage response market, based on several relevant parameters (such as product portfolio strength, phase of development and company size), [B] an insightful tree map representation of DNA damage response targeting therapeutics developers, based on their target therapeutic area and company size, [C] a world map representation highlighting the regional distribution of developers engaged in DNA damage response market, and [D] a grid representation illustrating the distribution of DNA damage response targeting therapeutics based on their phase of development, target therapeutic area, type of molecule, type of therapy, and route of administration.
  • Elaborate profiles of prominent players engaged in the development of DNA damage response targeting therapeutics. Each profile features a brief overview of the company, details related to its respective drug candidates, recent developments and an informed future outlook.
  • A detailed analysis of more than 250 completed, ongoing and planned clinical studies of various DNA damage response targeting therapeutics, based on several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status and study design, highlighting leading sponsors / collaborators and leading players (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful case study (for trials related to clinical DNA damage response targeting therapeutics, within the scope of the report).
  • An analysis of more than 150 peer-reviewed scientific articles related to DNA damage response targeting therapeutics, published during the period April 2020 to March 2021, highlighting the research focus within this niche industry segment. Additionally, it features an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, and analysis based on several relevant parameters, such as year of publication, type of publication, key research hubs, most popular authors, provision of grant awarded, target molecule, and most popular journals (in terms of number of articles published in the given time period and journal impact factor). Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of publication, grant support, journal impact factor, and number of target molecules under study.
  • An insightful multivariate scenario management analysis impacting adoption rates and price points taking into consideration more than 20 parameters.

The key objective of DNA damage response market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for DNA damage response market during the forecast period. Further, we have provided an informed estimate of the evolution of the market, during the forecast period 2021-2030, based on several relevant parameters, such as adoption trends, and expected price variations for these products. Additionally, the market report features the likely distribution of the current and forecasted opportunity within DNA damage response market across [A] target disease indications (acute myeloid leukemias, COVID-19, diabetic macular edemas, mesotheliomas, myelodysplastic syndromes, non-squamous non-small cell lung cancers, prostate cancers, and uterine serous carcinomas), [B] therapeutic areas (hematological malignancies, solid tumors, and other disorders), [C]  target molecule (APE/REF-1, casein kinase 2, CHK-1, C-Tak, DHODH, MAPKAPK2, p53, and WEE 1), [D] type of molecule (biologics and small molecule), [E] route of administration (oral drugs and intravenous drugs), and [F] key geographical regions (US, Canada, Denmark, France, Germany, Italy, Spain, UK, Australia, Singapore, and South Korea). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Benchmarking of Prominent Drug Candidate in DNA Damage Response Market Market Forecast and Opportunity Analysis in DNA Damage Response Market Future Market Trends in DNA Damage Response Market

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is DNA damage response?

Answer: The DNA damage response (DDR) comprises of orchestrated network of pathways that signal not only for repair of DNA lesions but also for activation of checkpoints, which are responsible for cell arrest at key points in the cell cycle. Importantly, high specificity and sensitivity to conventional therapies, coupled to minimal off target toxicity, have led to the use of DDR as a potential target for treatment of wider range of clinical conditions.

Question 2: How big is the DNA damage response market?

Answer: The DNA damage response market size is estimated to be worth $13 million in 2021.

Question 3: What is the projected market growth of the DNA damage response market?

Answer: The DNA damage response market is expected to grow at compounded annual growth rate (CAGR) of 73% during the forecast period 2021 – 2030.

Question 4: Who are the leading players in the DNA damage response market?

Answer: Examples of key companies engaged in DNA damage response market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aprea Therapeutics, AstraZeneca, Chordia Therapeutics, Mission Therapeutics, Repare Therapeutics and Senhwa Biosciences.

Question 5: How many drug candidates are currently being evaluated by players engaged in the DNA damage response market?

Answer: Over 90 drug candidates are currently being evaluated by players engaged in the DNA damage response market.

Question 6: How many articles related to the DNA damage response targeted therapeutics have been published?

Answer: More than 150 articles related to the DNA damage response have been published, focusing on safety, efficacy and mode of action DDR inhibitors.

Question 7: Which region emerged as the hub for companies engaged in the DNA damage response market?

Answer: North America emerged as the hub for companies engaged in the DDR Inhibitors market, with over 65% of the players established in the region.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com